Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Virol ; 66(2): 218-23, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11782930

ABSTRACT

In vitro incubation of human cytomegalovirus (Towne strain) with 8 U/ml human recombinant myeloperoxidase plus sodium chloride and glucose nearly abolished viral infectivity. To assay the effect on intracellular infection, cell toxicity of the enzymes was first studied. Even the high dose of 16 U/ml of recombinant myeloperoxidase plus 10 mU/ml glucose oxidase did not decrease MRC5 cell growth. By contrast, this dose reduced proliferation of activated THP1 cells. Even half of the myeloperoxidase dose proved slightly toxic to these cells. Non-cytotoxic concentrations of the reagents were used to monitor their effect on cytomegalovirus infection. In MRC5 cells, even the low dose of 4 U/ml myeloperoxidase plus glucose oxidase inhibited synthesis of cytomegalovirus early antigens, as tested by immunofluorescence. Viral release in the supernatant was decreased by 4 logs. In THP1 cells, which produce endogenously hydrogen peroxide, myeloperoxidase alone (8 U/ml) decreased the formation of early and late antigens by 53 and 44%, respectively.


Subject(s)
Antiviral Agents/pharmacology , Cytomegalovirus Infections/virology , Cytomegalovirus/drug effects , Peroxidase/pharmacology , Recombinant Proteins/pharmacology , Cell Division , Cell Line , Cytomegalovirus/pathogenicity , Fibroblasts/physiology , Fibroblasts/virology , Humans , Hydrogen Peroxide/metabolism , Macrophages/physiology , Macrophages/virology , Monocytes/physiology , Monocytes/virology , Peroxidase/genetics , Recombinant Proteins/genetics , Virus Replication/drug effects
2.
Cytotherapy ; 1(6): 447-53, 1999.
Article in English | MEDLINE | ID: mdl-20426545

ABSTRACT

BACKGROUND: Dendritic cell (DC)-based vaccine is a promising approach for cancer therapy. Pioneer trials have been conducted using DC generated in research conditions. There is now a need for generating DC in clinical grade conditions, including the use of closed systems, avoidance of FCS and respect of good manufacturing practices (GMP). METHODS: DC were generated from 84 leukapheresis products of 27 cancer patients enrolled in two Phase I/II trials of vaccination of either MAGE+tumors (n = 24) or prostate cancer (n = 3). Monocytes were seeded in culture bags in a serum-free medium supplemented with IL-4 and GM-CSF. After a 7 day culture, DC were collected and most were pulsed with various MAGE-derived peptides. RESULTS: After a short leukapheresis (mean time: 66 min; mean processed blood: 5 L), a mean of 6 x 10(9) WBC were collected, from which 2.25 x 10(9) were seeded. The culture procedure yielded a large number of DC (mean: 62 x 10(6) DC) harboring the expected phenotype of immature DC (CD1a(+) CD14(-) HLA-DR(+) CD80(+) CD86(+) CD83(-)). This phenotype was not altered by peptide loading. These DC, either fresh or thawed, were functionally effective invitro. Their s.c. and i.v. injections were devoid of any short-term side effect and associated with the induction of immune responses in the patients. DISCUSSION: Large numbers of functional immature clinical grade DC can be generated in a closed system from leukapheresis products in cancer patients. These results provide the basis for large-scale studies of cancer immunotherapy under improved safety conditions.


Subject(s)
Cancer Vaccines/therapeutic use , Cell Transplantation/methods , Dendritic Cells/cytology , Neoplasms/immunology , Neoplasms/therapy , Adult , Aged , Antigens, Neoplasm/biosynthesis , Cell- and Tissue-Based Therapy/methods , Culture Media, Serum-Free/pharmacology , Female , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , Immunotherapy/methods , Interleukin-4/metabolism , Leukapheresis/methods , Male , Melanoma-Specific Antigens , Middle Aged , Neoplasm Proteins/biosynthesis , Peptides/chemistry , Prostatic Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...